Maternal Ezetimibe Concentrations Measured in Breast Milk and Its Use in Breastfeeding Infant Exposure Predictions

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2024 Jan 26

PMID 38278872

Authors

Cindy H T Yeung

Julie Autmizguine

Pooja Dalvi

Audrey Denoncourt

Shinya Ito

Pamela Katz

Mehzabin Rahman

Yves Theoret

Andrea N Edginton

Affiliations

Soon will be listed here.

Abstract

Background: Lactating mothers taking ezetimibe, an antihyperlipidemic agent, may be hesitant to breastfeed despite the known benefit of breastfeeding to both mother and infant. Currently, no data exist on the presence or concentration of ezetimibe and its main active metabolite, ezetimibe-glucuronide (EZE-glucuronide), in human breast milk.

Methods: Voluntary breast milk samples containing ezetimibe and EZE-glucuronide were attained from lactating mothers taking ezetimibe as part of their treatment. An assay was developed and validated to measure ezetimibe and EZE-glucuronide concentrations in breast milk. A workflow that utilized a developed and evaluated pediatric physiologically based pharmacokinetic (PBPK) model, the measured concentrations in milk, and weight-normalized breast milk intake volumes was applied to predict infant exposures and determine the upper area under the curve ratio (UAR).

Results: Fifteen breast milk samples from two maternal-infant pairs were collected. The developed liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay showed an analytical range of 0.039-5.0 ng/mL and 0.39-50.0 ng/mL for ezetimibe and EZE-glucuronide, respectively. The measured concentrations in the breast milk samples were 0.17-1.02 ng/mL and 0.42-2.65 ng/mL of ezetimibe and EZE-glucuronide, respectively. The evaluated pediatric PBPK model demonstrated minimal exposure overlap in adult therapeutic dose and breastfed infant simulated area under the concentration-time curve from time zero to 24 h (AUC). Calculated UAR across infant age groups ranged from 0.0015 to 0.0026.

Conclusions: PBPK model-predicted ezetimibe and EZE-glucuronide exposures and UAR suggest that breastfeeding infants would receive non-therapeutic exposures. Future work should involve a 'mother-infant pair study' to ascertain breastfed infant plasma ezetimibe and EZE-glucuronide concentrations to confirm the findings of this work.

Citing Articles

Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding.

Suryavanshi S, Wang S, Hajducek D, Hamadeh A, Yeung C, Maglalang P Clin Pharmacokinet. 2024; 63(12):1735-1748.

PMID: 39586935 PMC: 11726907. DOI: 10.1007/s40262-024-01447-3.

Addressing health equity for breastfeeding women: primaquine for Plasmodium vivax radical cure.

Abla N, Marrast A, Jambert E, Richardson N, Duparc S, Almond L Malar J. 2024; 23(1):287.

PMID: 39334094 PMC: 11438061. DOI: 10.1186/s12936-024-05112-9.

References

Chowdhury R, Sinha B, Sankar M, Taneja S, Bhandari N, Rollins N . Breastfeeding and maternal health outcomes: a systematic review and meta-analysis. Acta Paediatr. 2015; 104(467):96-113. PMC: 4670483. DOI: 10.1111/apa.13102. View

Ip S, Chung M, Raman G, Trikalinos T, Lau J . A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. Breastfeed Med. 2009; 4 Suppl 1:S17-30. DOI: 10.1089/bfm.2009.0050. View

Chantry C, Howard C, Auinger P . Full breastfeeding duration and associated decrease in respiratory tract infection in US children. Pediatrics. 2006; 117(2):425-32. DOI: 10.1542/peds.2004-2283. View

Greer F, Sicherer S, Burks A . Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics. 2008; 121(1):183-91. DOI: 10.1542/peds.2007-3022. View

Mazer-Amirshahi M, Samiee-Zafarghandy S, Gray G, van den Anker J . Trends in pregnancy labeling and data quality for US-approved pharmaceuticals. Am J Obstet Gynecol. 2014; 211(6):690.e1-11. DOI: 10.1016/j.ajog.2014.06.013. View

Yeung C, Ito S, Autmizguine J, Edginton A . Incorporating Breastfeeding-Related Variability with Physiologically Based Pharmacokinetic Modeling to Predict Infant Exposure to Maternal Medication Through Breast Milk: a Workflow Applied to Lamotrigine. AAPS J. 2021; 23(4):70. DOI: 10.1208/s12248-021-00599-5. View

Yeung C, Fong S, Malik P, Edginton A . Quantifying breast milk intake by term and preterm infants for input into paediatric physiologically based pharmacokinetic models. Matern Child Nutr. 2020; 16(2):e12938. PMC: 7083422. DOI: 10.1111/mcn.12938. View

van Heek M, France C, Compton D, McLeod R, Yumibe N, Alton K . In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 1997; 283(1):157-63. View

Patrick J, Kosoglou T, Stauber K, Alton K, Maxwell S, Zhu Y . Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos. 2002; 30(4):430-7. DOI: 10.1124/dmd.30.4.430. View

10.

Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T . Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor.... Clin Pharmacol Ther. 2006; 79(3):206-17. DOI: 10.1016/j.clpt.2005.11.004. View

11.

Oswald S, Konig J, Lutjohann D, Giessmann T, Kroemer H, Rimmbach C . Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics. 2008; 18(7):559-68. DOI: 10.1097/FPC.0b013e3282fe9a2c. View

12.

de Waart D, Vlaming M, Kunne C, Schinkel A, Oude Elferink R . Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009; 37(8):1698-702. DOI: 10.1124/dmd.108.026146. View

13.

Maharaj A, Barrett J, Edginton A . A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013; 15(2):455-64. PMC: 3675728. DOI: 10.1208/s12248-013-9451-0. View

14.

Rodgers T, Leahy D, Rowland M . Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005; 94(6):1259-76. DOI: 10.1002/jps.20322. View

15.

Rodgers T, Rowland M . Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006; 95(6):1238-57. DOI: 10.1002/jps.20502. View

16.

Rodgers T, Rowland M . Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007; 24(5):918-33. DOI: 10.1007/s11095-006-9210-3. View

17.

Schmitt W . General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro. 2007; 22(2):457-67. DOI: 10.1016/j.tiv.2007.09.010. View

18.

Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S . Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos. 2004; 32(3):314-20. DOI: 10.1124/dmd.32.3.314. View

19.

Shiran M, Proctor N, Howgate E, Rowland-Yeo K, Tucker G, Rostami-Hodjegan A . Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica. 2006; 36(7):567-80. DOI: 10.1080/00498250600761662. View

20.

Rostami-Hodjegan A, Tucker G . Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov. 2007; 6(2):140-8. DOI: 10.1038/nrd2173. View